The Food and Drug Administration and US Patent and Trademark Office will hold a public listening session in January to hear input on increasing access to medicines, according to a Federal Register notice scheduled to be published Nov. 7.
The meeting is part of efforts to implement President Joe Biden’s July 2021 executive order to promote competition, including by ensuring “that the patent system, while incentivizing innovation, does not unjustifiably delay generic drug and biosimilar competition beyond that reasonably contemplated by applicable law.”
The session—scheduled for Jan. 19 at the PTO headquarters in Alexandria, Va.—will focus on several questions the ...